DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company

Monthly information regarding the total number of voting rights and total number of shares of the Company

                                                                                                                                                                                                                                                                       

Monthly information regarding the total number of voting rights and

total number of shares of the Company

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
03/16/202054,927,187 



Total gross of voting rights: 54,927,187



 
 



Total net* of voting rights:  54,863,636



 

* Total net = total number of voting rights attached to shares – shares without voting rights

Attachment

EN
26/03/2020

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K a...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced: The audited financial statements for the year ended December 31, 2024 we...

April 11, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies publie son « Form 10-K » américain et son Document d’...

DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2024 Châtillon, France, le 11 avril 2025 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique au stade clinique (la « Société »), a annoncé aujourd'hui que : Les états financiers audités pour l’exercice 2024 ont été arrêtés par le Conseil d’administration le 11 avril 2025, et que ceux-ci ne présentent pas de changement par rapport aux états financ...

April 11, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 M...

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrantsDBV sufficiently funded t...

March 28, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Annonce un Financement pouvant atteindre 306,9 millio...

DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la... Châtillon, France, le 28 mars (3h30 CET) 2025 DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la commercialisation du produit aux États-Unis, si le BLA est Approuvé DBV sécurise u...

March 28, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Re...

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results1 COMFORT Children supplemental safety study i...

March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch